Company Description
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases.
It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma.
In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia.
The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3.
The company was incorporated in 2017 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2017 |
| IPO Date | Oct 11, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 229 |
| CEO | David Chang |
Contact Details
Address: 210 East Grand Avenue South San Francisco, California 94080 United States | |
| Phone | 650 457 2700 |
| Website | allogene.com |
Stock Details
| Ticker Symbol | ALLO |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001737287 |
| CUSIP Number | 019770106 |
| ISIN Number | US0197701065 |
| Employer ID | 82-3562771 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, Chief Executive Officer and Director |
| Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder and Executive Chairman |
| Joshua A. Kazam | Co-Founder and Director |
| Dr. Zachary J. Roberts M.D., Ph.D. | Executive Vice President of Research and Development and Chief Medical Officer |
| Geoffrey M. Parker | Executive Vice President and Chief Financial Officer |
| Benjamin M. Beneski | Senior Vice President and Chief Technical Officer |
| Earl M. Douglas Esq. | Senior Vice President, General Counsel, Compliance Officer and Corporate Secretary |
| Susan R. Lundeen | Chief People Officer |
| Christine Cassiano | Executive Vice President, Chief Corporate Affairs and Brand Strategy Officer |
| Annie Yoshiyama | SVice President and Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| May 9, 2025 | SCHEDULE 13G/A | Filing |
| Apr 30, 2025 | ARS | Filing |
| Apr 30, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 30, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 21, 2025 | 144 | Filing |
| Apr 17, 2025 | SCHEDULE 13G/A | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 14, 2025 | 144 | Filing |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |